LivaNova receives FDA clearance for VNS in obstructive sleep apnea — first neuromodulation OSA therapy
Summary
LivaNova announced FDA clearance for an expanded indication of their VNS Therapy System to include obstructive sleep apnea, making it the first vagus nerve stimulation therapy cleared for OSA in the US. The clearance enables LivaNova to offer a VNS solution for sleep apnea patients who already have LivaNova devices for epilepsy or depression, potentially treating multiple conditions with a single implanted system.
Why it matters
VNS for OSA combined with existing epilepsy and depression indications creates a multi-indication single-implant value proposition unprecedented in neuromodulation. The ability to program a single LivaNova VNS device for three conditions simultaneously could significantly increase the device's clinical and economic value per implant.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial